Phio Pharmaceuticals Corp. Stock price

Equities

PHIO

US71880W4024

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.68 USD -6.35% Intraday chart for Phio Pharmaceuticals Corp. -19.05% -10.53%
Sales 2023 * - Sales 2024 * - Capitalization 1.66M
Net income 2023 * -12M Net income 2024 * -13M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-0.11 x
P/E ratio 2024 *
-0.19 x
Employees 10
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.24%
More Fundamentals * Assessed data
Dynamic Chart
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies CI
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research CI
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders MT
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders CI
HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating MT
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas CI
Phio Pharmaceuticals Shares Rise After Data Shows Intasyl Compound Enhances Tumor Control MT
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer CI
Top Premarket Decliners MT
Top Midday Gainers MT
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894 CI
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Phio Pharmaceuticals Completes $4 Million Securities Offering MT
More news
1 day-6.35%
1 week-19.05%
Current month-37.04%
1 month-30.26%
3 months-10.99%
6 months-53.74%
Current year-10.53%
More quotes
1 week
0.66
Extreme 0.66
0.77
1 month
0.66
Extreme 0.66
1.15
Current year
0.50
Extreme 0.5
1.15
1 year
0.50
Extreme 0.5
12.27
3 years
0.50
Extreme 0.5
34.80
5 years
0.50
Extreme 0.5
346.50
10 years
0.50
Extreme 0.5
293 040.29
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 12-06-18
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 17-09-14
Members of the board TitleAgeSince
Chief Executive Officer 73 12-06-18
Director/Board Member 73 22-05-01
Director/Board Member 64 13-04-17
More insiders
Date Price Change Volume
24-03-28 0.68 -6.35% 128,814
24-03-27 0.7261 -0.53% 54,142
24-03-26 0.73 -3.95% 56,809
24-03-25 0.76 +4.84% 92,008
24-03-22 0.7249 -13.70% 439,082

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL compounds are designed to precisely target specific proteins that reduce the body's ability to fight cancer without the need for specialized formulations or drug delivery systems, and are designed to make immune cells effective in killing tumor cells. Its lead product candidate, PH-762, is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells? ability to kill cancer cells and is a clinically validated target in immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.68 USD
Average target price
4 USD
Spread / Average Target
+488.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Phio Pharmaceuticals Corp. - Nasdaq